Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240

TMC240 is a very poorly soluble and poorly permeating HIV protease inhibitor. In order to enhance its oral bioavailability, a fast dissolving inulin-based solid dispersion tablet was developed. During the dissolution test in water (0.5% or 1.0% SLS), this tablet released at least 80% of TMC240 within 30 min, while a tablet with the same composition, but manufactured as physical mixture, released only 6% after 2 h. In a Subsequent single-dose Study in dogs (200 mg of TMC240), plasma concentrations of TMC240 remained below the lower limit of quantification (<1.00 ng/mL) in all animals (n = 3 per tested formulation), except in one dog receiving the inulin solid dispersion tablet (C-max = 1.8 ng/mL, AUC(0-7) (h), = 3.0 ng h/mL). In the latter treatment group, ritonavir co-administration (10 mg/kg b.i.d.) increased TMC240 exposure more than 30-fold (mean AUC(0-7 h), = 108 ng h/mL: F-rel = 3588%). Exposure was also 16-fold higher than after TMC240 administration as PEG400 suspension in the presence of ritonavir (AUC(0-7 h), = 6.7 ng h/mL). The Current data demonstrate that a solid dispersion of TMC240 in an mulin matrix allows considerable improvement in the release of poorly water-soluble TMC240, both in vitro in the presence of a surfactant and in Vivo upon Oral administration. (C) 2009 Elsevier B.V. All rights reserved.